MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-06-2026
Myriad Genetics Net Debt 2011-2026 | MYGN
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Myriad Genetics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.8 M | -50 M | -77.4 M | - | - | 115 M | 184 M | -31.9 M | 45 M | -68.5 M | -64.1 M | -64.8 M | -104 M | -86.4 M | -52.7 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 184 M | -104 M | -21.4 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Co-Diagnostics
CODX
|
-10.6 M | $ 1.29 | -20.86 % | $ 1.72 M |  USA |
 |
Agilent Technologies
A
|
1.24 B | $ 111.67 | -1.39 % | $ 33.9 B | USA |
 |
Castle Biosciences
CSTL
|
-106 M | $ 19.22 | 1.8 % | $ 557 M | USA |
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Fulgent Genetics
FLGT
|
-53.3 M | $ 15.84 | -2.16 % | $ 479 M | USA |
 |
Aspira Women's Health
AWH
|
-512 K | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Illumina
ILMN
|
-494 M | $ 141.26 | -1.38 % | $ 22.5 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M |  Britain |
 |
Interpace Biosciences
IDXG
|
-1.32 M | $ 1.8 | - | $ 7.96 M | USA |
 |
CareDx, Inc
CDNA
|
-39.2 M | $ 19.81 | -3.34 % | $ 1.06 B | USA |
 |
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-3.13 M | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
213 M | $ 93.52 | -3.26 % | $ 6.31 B | USA |
 |
Medpace Holdings
MEDP
|
-360 M | $ 417.74 | -0.34 % | $ 12.1 B | USA |
 |
Mettler-Toledo International
MTD
|
2.06 B | $ 1 039.9 | -0.19 % | $ 21.4 B |  Schweiz |
 |
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | China |
 |
NeoGenomics
NEO
|
187 M | $ 8.28 | -0.96 % | $ 1.06 B | USA |
 |
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
71.3 M | $ 18.7 | -1.22 % | $ 419 M | USA |
 |
Natera
NTRA
|
-177 M | $ 188.14 | -4.45 % | $ 18.5 B | USA |
 |
Charles River Laboratories International
CRL
|
1.98 B | $ 154.29 | -3.04 % | $ 7.65 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-916 M | - | - | $ 19.8 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 25.27 | -0.9 % | $ 24 B |  Niderland |
 |
Guardant Health
GH
|
1.15 B | $ 94.56 | -4.16 % | $ 11.9 B | USA |
 |
Personalis
PSNL
|
-117 M | $ 6.45 | -3.95 % | $ 576 M | USA |
 |
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | USA |
 |
ICON Public Limited Company
ICLR
|
4.63 B | $ 117.67 | 0.5 % | $ 9.71 B |  Irlanda |
 |
Senseonics Holdings
SENS
|
-4.15 M | $ 5.7 | -2.06 % | $ 238 M | USA |
 |
Soleno Therapeutics
SLNO
|
-19.5 M | $ 52.99 | - | $ 2.69 B | USA |
 |
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | Niderland |
 |
Biomerica
BMRA
|
-1.94 M | $ 2.36 | -2.07 % | $ 5.42 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 251.95 | -0.81 % | $ 21 B | USA |
 |
Thermo Fisher Scientific
TMO
|
29.6 B | $ 439.75 | -1.87 % | $ 166 B | USA |
 |
Trinity Biotech plc
TRIB
|
55.4 M | $ 0.57 | -1.7 % | $ 205 M | Irlanda |
 |
Celcuity
CELC
|
-28.1 M | $ 134.2 | -0.39 % | $ 6.27 B | USA |
 |
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | Israel |
 |
Twist Bioscience Corporation
TWST
|
-107 M | $ 48.67 | -8.08 % | $ 2.91 B | USA |
 |
Neogen Corporation
NEOG
|
751 M | $ 8.22 | -2.49 % | $ 1.78 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 187.17 | -0.41 % | $ 20.8 B | USA |
 |
Invitae Corporation
NVTA
|
-239 M | - | - | $ 21.2 M | USA |